focus -WSS

focus

author：explore 2025-09-29 02:09:06 - browse：42

Vincent Major (left) and Cristina Gonzalez at the prompt-a-thon organized by NYU Langone. Courtesy Joe Carrotta/ NYU Langone

NEW YORK — A fourth-year medical student, a music therapist, a child psychiatrist, and a physician-researcher stared at their laptops, puzzling over the combination of words that would make a supposedly intelligent system — NYU Langone’s customized version of ChatGPT — think about health care problems in a way that was useful to them.

As part of a “prompt-a-thon” in August at the medical center’s science building, the group had been charged with analyzing a patient record around the theme of equity using NYU’s HIPAA-compliant implementation of the buzzy OpenAI technology that can interpret language and generate text based on queries.

After a morning of mini-lectures, participants broke off into assigned groups and dove into NYU Langone’s newly launched prompting interface. Representatives from Microsoft, which makes the artificial intelligence tool accessible through its cloud services, were on hand to ensure everything ran smoothly as about 70 workshop participants from across the academic medical center put prompts into the system around themes including research, clinical applications, and patient education.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Latigo launches with $135 million for Vertex

WSS

First U.S. drug developed to treat liver disease MASH is approved

Male and female sex labels in research insufficient, scientists say

President Biden's budget: Here's what you might have missed

EPA limits use of carcinogenic gas for sterilizing medical devices

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Abbott's new heart device gets FDA advisory panel nod

knowledge

focus

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Ebola: Gilead Sciences antiviral shows promise as new treatment

Psychedelics group wrestles with new pharma identity

Ebola: Gilead Sciences antiviral shows promise as new treatment

Virginia high school admissions case could be legal follow

UCLA team creates talking throat patch for voice disorders

Supreme Court strikes down use of affirmative action

FDA advisers back CAR

Psychedelics group wrestles with new pharma identity

Steward Health Care Massachusetts hospitals face fiscal disaster

focus

FDA advisers back CAR

How to save health care price transparency rules

Pushing for an NIH office for post

Abbott's new heart device gets FDA advisory panel nod

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Pushing for an NIH office for post

hotspot

entertainment

explore

focus